NCT05580562 2025-08-26
ACTION
Jazz Pharmaceuticals
Phase 3 Recruiting
Clinical Trials
5 trialsNCT04617002 2025-08-20
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
Jazz Pharmaceuticals
Approved for marketing
NCT03295396 2025-07-28
ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
Jazz Pharmaceuticals
Phase 2 Terminated
NCT03416530 2025-02-14
ONC201 in Pediatric H3 K27M Gliomas
Jazz Pharmaceuticals
Phase 1 Terminated
NCT03134131 2022-03-14
Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas
Jazz Pharmaceuticals
No longer available